EFFECTIVE DATE: October 26, 2010
Calmare Therapeutics Incorporated (CTI) maintains the Web Site calmaretherapeutics.com (the "Site") for your information, education, communication and personal enjoyment. Access to and use of this Site are subject to the terms and conditions set forth below:
Materials available on the Site are protected by the copyright laws of the United States and other countries. Copyright Calmare Therapeutics Incorporated © 1999-2017. All rights reserved.
All links to this Site must be approved in writing by CTI, except that CTI consents to links in which the link and the pages that are activated by the link do not: (a) create frames around any page on this Site or use other techniques that alter in any way the visual presentation or appearance of any content within this Site; (b) misrepresent your relationship with CTI; (c) imply that CTI approves or endorses you, your web site, or your service or product offerings; and (d) present false or misleading impressions about CTI or otherwise damage the goodwill associated with the CTI name or trademarks. As a further condition to being permitted to link to this Site, you agree that CTI may at any time, in its sole discretion, terminate permission to link to this Site. In such event, you agree to immediately remove all links to this Site and to cease using any CTI trademark.
CTI is committed to protecting the privacy needs of children. CTI does not knowingly collect information from children under the age of 13, and no part of the Site is structured to attract any person under the age of 13.
CTI uses your Personal Information and/or Technology Information (collectively, Information) to provide you with services and to help us better understand your needs and interests. Specifically, we use your Information to communicate with you and to provide service and support. If you choose to have a relationship with CTI, such as a contractual or other business relationship or partnership, we will naturally continue to contact you in connection with that business relationship.
CTI will not sell, rent or lease your Personal Information to others. CTI will not share your Information with any third parties without your permission, unless to: (i) respond to duly authorized information requests of government authorities, (ii) comply with any law, regulation, subpoena, or court order, (iii) help prevent fraud or to enforce or protect the rights and properties of CTI, or (iv) to protect the personal safety of CTI employees and third parties on CTI property.
CTI is committed to protecting the Information you provide us. To prevent unauthorized access or disclosure, to maintain data accuracy, and to ensure the appropriate use of the Information, CTI has in place appropriate physical, electronic and managerial procedures to safeguard and secure the Information we collect online.
EFFECTIVE DATE: April 30, 2007
CTI reserves the right to cease offering any or all of the RSS feeds at any time or to require you to cease distributing any or all of the feeds at any time for any reason. CTI assumes no liability for your activities in connection with the RSS feeds or for your use of the feeds in connection with your web site.
EFFECTIVE DATE: April 9, 2007
It is the policy of Calmare Therapeutics Incorporated ("CTI") to respect the intellectual property of others and thus to respond to effective notices of alleged infringement of copyrighted material where (i) the copyrighted material is available at, or from, a system or network controlled or operated by or for CTI or where (ii) CTI, by providing or using an information location tool, such as a directory, index, reference, pointer, or hypertext link, refers or links a third party to a site that contains the copyrighted material.
If you are alleging that copyrighted material may have been or is being infringed, then you may notify CTI, pursuant to the U.S. Online Copyright Infringement Liability Limitation Act of the U.S. Digital Millennium Copyright Act, 17 U.S.C. §512 (c), by sending a notice to the address listed below. Such notice must include the following to be effective:
If material that you have posted to a system or network controlled or operated by or for CTI has been removed or disabled, you may file a counter notice pursuant to 17 U.S.C. §512 (g). To be effective, the counter notice must be a written communication sent to the address listed below that includes the following:
All written notices should be sent to the following Designated Agent:
Calmare Therapeutics Incorporated
1375 Kings Hwy. STE 400
Fairfield, CT 06824-5380